Clinical development
Pfizer Ignite’s team of experts works with you on everything from drafting clinical development plans in the IND-enabling phase all the way through to assessing safety and efficacy data.
With capabilities spanning multiple therapeutic areas (oncology, inflammation & immunology, and hematology), our team of R&D scientists offer support throughout the preclinical R&D process for small or large molecules, including:
Pfizer Ignite’s team of experts works with you on everything from drafting clinical development plans in the IND-enabling phase all the way through to assessing safety and efficacy data.
Collaboration with Pfizer Ignite enables our biotech partners to benefit from our global manufacturing network, which includes more than 35 sites across six continents. From these facilities, we can reliably deliver technical expertise, regulatory support and global clinical supply to our biotech partners across the world.
Pfizer Ignite employs a variety of cross-cutting platforms, both for data management and analysis as well as drug development, in order to improve efficiency and apply the best-practice from our industry to give therapies the highest possible chance of success.
We know what it takes to get a breakthrough to market. Pfizer is the current end-to-end clinical (FIH to approval) success-rate leader, with an industry high of 21% in 2020. That comes from our in-depth understanding of the process and how to navigate it – an understanding that we share with our partners to co-create a meticulous and bespoke roadmap to accelerate their candidates through the clinical phases.
This includes: